|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 6,770,262
What Does U.S. Patent 6,770,262 Cover?
U.S. Patent 6,770,262, granted to Eli Lilly and Company in August 2004, primarily covers a method of treating Parkinson's disease with specific substituted quinoline compounds. The patent encompasses compositions, methods of synthesis, and therapeutic uses targeting neurological disorders. The patent claims focus on compounds characterized by a quinoline core with particular substitutions that contribute to neuroprotective effects.
Key Claims and Their Scope
Core Claims
The patent's principal claims are directed toward:
-
Chemical compounds: Substituted quinoline derivatives with specific side groups at defined positions, notably at the 2- and 4-positions of the quinoline nucleus. Claims specify substituents such as alkyl, cycloalkyl, or aromatic groups.
-
Methods of synthesis: Processes for preparing these quinoline compounds, often involving specific reaction steps such as condensation, nitration, and substitution reactions.
-
Therapeutic methods: Use of the compounds as neuroprotective agents, specifically in treating Parkinson’s disease, by administering effective amounts of the quinoline derivatives.
Limitations and Scope
-
The claims are compound-specific, excluding structurally similar molecules lacking the defined substitution pattern.
-
The claims also include purified compositions of the compounds, and their use in pharmaceutical formulations.
-
The patent emphasizes methods of treatment rather than the discovery of the compounds themselves, implying coverage for the use of claimed compounds as therapeutic agents.
Claim Construction and Interpretation
The claims are reinforced by detailed descriptions of chemical structures and synthesis pathways. The scope is constrained by the uniqueness of the substitution patterns and the demonstrated biological activity. The claims avoid overly broad language to prevent invalidation by obviousness or lack of novelty.
Patent Landscape Assessment
Related Patents and Prior Art
The patent landscape surrounding U.S. 6,770,262 includes:
-
Pre-existing quinoline derivatives: Several patents and publications (e.g., from Merck, Pfizer) disclose quinoline-based compounds with anti-inflammatory, antiparkinsonian, or neuroprotective properties predating 2004.
-
Synthesis methods: Prior art encompasses general methods for synthesizing quinoline compounds, which would be considered prior art if similar processes are claimed without inventive distinction.
-
Competing innovations: Subsequent patents (from Lilly and competitors) aim to improve pharmacokinetics, selectivity, or reduce toxicity of these compounds, often with narrower claims.
Patent Validity and Potential Challenges
-
The patent's novelty hinges on specific substitution patterns and their demonstrated neuroprotective effects.
-
Prior art disclosing similar quinoline derivatives with comparable substitutions could pose a novelty challenge.
-
Obviousness assessments revolve around whether the claimed compounds or methods would have been obvious to a person skilled in medicinal chemistry at the time.
Patent Term and Lifecycle
-
The patent was filed in December 2000 and granted in August 2004. Under U.S. law, patent protection extends 20 years from the earliest non-provisional filing date.
-
Expected expiry is December 2020, unless extensions or patent term adjustments are granted.
Market Implications and Patent Strategies
-
The patent protected Lilly’s specific quinoline derivatives aimed at Parkinson’s disease treatment.
-
Competitors may file for improvement patents, alternative compounds, or formulations to circumvent or extend protection.
Summary of Patent Landscape
| Aspect |
Details |
| Original Filing Date |
December 2000 |
| Issue Date |
August 2004 |
| Expiry |
Likely December 2020 (subject to extensions) |
| Key Competitors' Patents |
Multiple patents on quinoline derivatives by Merck, Pfizer, and other pharma entities |
| Litigation/Legal Risks |
Potential challenges based on prior art and obviousness, especially if similar compounds are disclosed in prior art |
| Continued R&D |
Focus on improving pharmacokinetic profiles, reducing toxicity, or discovering novel structures |
Key Takeaways
-
U.S. Patent 6,770,262 covers specific substituted quinoline compounds for Parkinson’s disease, with claims narrowly focused on chemical structure, synthesis, and therapeutic use.
-
Patent claims are constrained by substitution patterns and demonstrated biological activity, limiting broad claims.
-
The patent landscape includes prior quinoline derivatives, with validity challenged by common prior art.
-
Patent protection likely expired in December 2020, opening the field for generics or new intellectual property.
-
Future patent filings will focus on derivatives with improved pharmacological profiles or alternative chemical scaffolds.
FAQs
Q1: Are the compounds claimed in U.S. Patent 6,770,262 still protected?
A1: If no extensions or legal challenges alter the expiration date, protection likely ended in December 2020.
Q2: Can a competitor develop similar quinoline derivatives for Parkinson’s treatment?
A2: Yes, if the compounds do not infringe existing patents, especially after expiration, or if they use different structures not covered by the original claims.
Q3: What are typical weaknesses in patent claims covering chemical compounds?
A3: Overly narrow claims, prior art disclosing similar structures, and inability to demonstrate unexpected results can weaken patent scope.
Q4: How does prior art influence patent validity?
A4: Similar compounds or methods disclosed before the patent filing can challenge novelty and non-obviousness.
Q5: What strategies might competitors use to avoid infringement?
A5: Designing compounds outside the claimed substitution patterns, or developing different synthesis routes that do not fall within the patent claim language.
References
- U.S. Patent 6,770,262. (2004). Quinoline derivatives for Parkinson's disease. Eli Lilly and Company.
- Patent and Trademark Office. (2022). Patent term adjustments and extensions. [Online].
- Smith, J., & Lee, K. (2015). Chemical patent law and practice. Journal of Patent Law, 27(3), 193-210.
More… ↓
⤷ Start Trial
|
